Anthracycline chemotherapy
-
This study’s goal was to assess the most prevalent short-term side effects experienced by patients with localized breast cancer, undergoing chemotherapy based on anthracyclines and taxane-containing treatments, at the medical oncology department of the Mohammed VI University Hospital of Marrakech, Morocco.
8p vishanshan 27-06-2024 1 1 Download
-
Chemotherapeutic agents such as anthracyclines and taxanes are commonly used in the neoadjuvant setting. Bevacizumab is an antibody which binds to vascular endothelial growth factor A (VEGFA) and inhibits its receptor interaction, thus obstructing the formation of new blood vessels.
14p vibransone 28-03-2024 4 2 Download
-
The combination of taxanes and anthracyclines is still the mainstay of chemotherapy for early breast cancer. Capecitabine is an active drug with a favorable toxicity profile, showing strong anti-tumor activity against metastatic breast cancer.
11p vileonardodavinci 23-12-2023 2 2 Download
-
Anthracycline-induced cardiotoxicity is an irreversible cardiac cell injury. Therefore, it’s very important to identify influencing factors of anthracycline-induced subclinical cardiotoxicity (AISC). This study was designed to analyze the influencing factors of AISC in patients with diffuse large B-cell lymphoma (DLBCL) treated with the (R)- CHOP chemotherapy regimen.
8p vialfrednobel 23-12-2023 3 3 Download
-
The clinical application of anthracycline chemotherapy is hindered due to the cumulative dosedependent cardiotoxicity followed by the oxidative stress initiated during the mechanism of action of anthracyclines.
17p vischultz 20-10-2023 1 1 Download
-
Current treatment of acute leukemia is based on anthracycline chemotherapy. Anthracyclines, despite improving patient survival, have serious cardiotoxicity and therefore cardiac monitoring should be a priority.
9p visharma 20-10-2023 5 2 Download
-
The impact of pectoralis muscle mass index (PMI) on cardiac events is not well studied in cancer patients, especially in those who have received chemotherapy with high potential cardiac toxicity such as anthracyclines.
8p vikolindagrabar 27-07-2022 6 2 Download
-
Canine hemangiosarcoma (HSA) is an aggressive cancer arising from multipotential bone marrowderived stem cells. Anthracycline chemotherapy drugs have been the mainstay adjuvant chemotherapy following surgery with only modest improvement in survival and an attendant risk for adverse events.
12p vidarwin 23-02-2022 10 1 Download
-
Pegylated liposomal doxorubicin (PLD) is an improved formulation of doxorubicin with comparable effectiveness but significantly lower cardiotoxicity than conventional anthracycline. This study aimed to evaluate the real-world effectiveness and safety of PLD versus epirubicin as neoadjuvant or adjuvant treatment for breast cancer.
11p vielonmusk 21-01-2022 12 0 Download
-
Eribulin or capecitabine monotherapy is the next cytotoxic chemotherapy option for patients with metastatic or recurrent breast cancer who have previously received an anthracycline or a taxane. However, it is unclear what factors can guide the selection of eribulin or capecitabine in this setting, and prognostic factors are needed to guide appropriate treatment selection.
10p vielonmusk 21-01-2022 12 0 Download
-
To evaluate the efficacy and safety of recombinant human serum albumin /granulocyte colonystimulating factor (rHSA/G-CSF) in breast cancer following receipt of cytotoxic agents. The prospective randomized controlled trials demonstrated that rHSA/G-CSF was efficacious and welltolerated with an approachable frequency and expense of application for prophylactic management of agranulocytosis.
11p vianrose2711 27-04-2021 12 2 Download
-
The HER2 gene has been established as a valid biological marker for the treatment of breast cancer patients with trastuzumab and probably other agents, such as paclitaxel and anthracyclines. The TOP2A gene has been associated with response to anthracyclines.
16p vijisoo2711 29-09-2020 6 2 Download
-
Current guidelines recommend anthracycline-based chemotherapy primarily with doxorubicin either as monotherapy or in combination with ifosfamide as the first-line treatment for most advanced STS subtypes. Therapeutic options after failure of doxorubicin and/or ifosfamide are limited.
21p vijennie2711 29-09-2020 15 0 Download
-
Adjuvant chemotherapy (AC) improves survival among patients with operable breast cancer. However, the effect of delay in AC initiation on survival is unclear. We performed a systematic review and metaanalysis to determine the relationship between time to AC and survival outcomes.
10p vijennie2711 29-09-2020 15 1 Download
-
Neoadjuvant chemotherapy (NAC) is one of the standard care regimens for patients with resectable early-stage breast cancer. It would be advantageous to determine the chemosensitivity of tumors before initiating NAC. One of the parameters potentially compromising such chemosensitivity would be a hypoxic microenvironment of cancer cells.
10p virose2711 24-09-2020 38 2 Download
-
Dose-dense sequential chemotherapy including anthracyclines and taxanes has been established in the adjuvant setting of high-risk operable breast cancer. However, the preferable taxane and optimal schedule of administration in a dose-dense regimen have not been defined yet.
14p vilisa271 22-09-2020 10 0 Download
-
Neoadjuvant Chemotherapy (NC) including trastuzumab induces a high rate of pathological Complete Responses (pCR) in patients with locally advanced HER2-overexpressing Breast Cancer (BC), but is penalized by a severe cardiotoxicity when combined with anthracyclines.
12p vialabama2711 21-09-2020 12 0 Download
-
Anthracycline adjuvant therapy has taken a particular role in the treatment of early stage breast cancer with an associated decrease in rates of both relapse and death. Their success however has been limited by their myelosuppression and their well-established risk of cardiac dysfunction.
5p vialabama2711 21-09-2020 11 1 Download
-
Anthracycline and taxane are classes of drugs that are frequently used in the adjuvant and palliative settings of metastatic breast cancer (MBC); however, treatment failure occurs in most cases. Limited data demonstrated favorable response in MBC after previous taxane-based treatment.
8p viamsterdam 18-09-2020 13 2 Download
-
Anthracycline-based adjuvant chemotherapy improves survival in patients with high-risk node-negative breast cancer (BC). In this setting, prognostic factors predicting for treatment failure might help selecting among the different available cytotoxic combinations.
11p vimoscow2711 29-08-2020 8 1 Download